Mrs. Shradha Sinha | Endocrinology | Best Researcher Award

Published on by Leadership and Management

Mrs. Shradha Sinha | Endocrinology | Best Researcher Award

Central Drug Research Institute | India

Author Profile

Scopus

Early Academic Pursuits

Shradha Sinha’s academic journey reflects a solid foundation in the life sciences, particularly in zoology, with a deepening interest in biomedical research. Her formative education laid the groundwork for her specialization in musculoskeletal biology, where she honed her understanding of complex biological systems. Driven by scientific curiosity and the desire to make a tangible impact in health-related fields, she excelled in competitive national-level examinations such as the CSIR-NET Junior Research Fellowship and the GATE Life Sciences assessment. These academic milestones not only validated her expertise but also opened doors to high-quality research opportunities. From the outset, her academic inclinations were clearly aligned with solving real-world health challenges through biological research.

Professional Endeavors

Currently serving as a Senior Research Fellow at the Central Drug Research Institute, Shradha Sinha plays a key role in advancing preclinical and translational research related to bone health and osteoarthritis. Her professional path demonstrates a seamless progression from academic training to applied biomedical research. Within her institutional role, she has taken on increasingly complex projects, collaborating across disciplines and managing multifaceted experimental designs. Her contributions to scientific inquiry are not limited to routine bench work but extend to the conception, execution, and dissemination of research projects with therapeutic relevance. Shradha’s ability to translate conceptual frameworks into data-driven discoveries showcases her as a well-rounded professional within the biomedical sciences.

Contributions and Research Focus

Shradha’s research contributions are situated at the intersection of bone biology, nutraceuticals, and pharmacological innovation. Her body of work reflects a dual focus on natural product-based therapeutics and synthetic pharmacological agents for skeletal diseases, particularly osteoporosis and osteoarthritis. One of her noteworthy projects involved evaluating the flavonoid content of banana pulp and peel and assessing their role in bone regeneration. This study provided novel evidence supporting the use of banana-derived compounds in mitigating bone loss and enhancing osteoblast differentiation—paving the way for low-cost, dietary-based interventions in bone health. Published in a high-impact journal, this work demonstrates both scientific rigor and translational potential.

In a separate but complementary study, she investigated the effects of a kappa-opioid receptor agonist (U50,488H) in the context of osteoarthritis. Her findings revealed that this agent could reduce cartilage degradation, inhibit chondrocyte hypertrophy, and prevent bone loss—adding a pharmacological dimension to her research portfolio. Together, these projects underscore her commitment to advancing therapeutic strategies through both natural and synthetic avenues, addressing the burden of degenerative bone diseases with a multifaceted approach. Additionally, her contributions include 11 peer-reviewed publications, a book chapter, and a patent, reflecting both productivity and innovation in her research output.

Accolades and Recognition

Although still in the early phase of her career, Shradha has already distinguished herself through her research productivity and academic excellence. Her success in securing nationally competitive fellowships and authoring high-quality publications signals her standing within the scientific community. The publication of her work in reputed journals, as well as her involvement in patented innovations, points to the recognition she has garnered for the originality and relevance of her work. Her interdisciplinary research has received commendation not only from peers but also from institutional mentors and collaborators. These accolades reflect her potential to emerge as a leading figure in musculoskeletal research in the years ahead.

Impact and Influence

Shradha’s research is poised to make a significant impact in both scientific and public health domains. Her exploration of nutraceuticals aligns well with growing global interest in functional foods and natural therapies for chronic conditions. By investigating the therapeutic roles of readily available substances like banana peel extracts, she is contributing to the development of cost-effective solutions that may benefit populations with limited access to conventional medicine. Her work with opioid receptor agonists also addresses a major gap in osteoarthritis management, offering promising insights into non-traditional pathways for intervention. Collectively, her contributions are bridging gaps between laboratory discoveries and real-world applications, enhancing the relevance of biomedical science to broader societal needs.

Legacy and Future Contributions

Looking ahead, Shradha Sinha is well-positioned to expand her influence in biomedical research, particularly in the area of skeletal health. Her ongoing commitment to investigating novel therapeutic agents and her interdisciplinary approach suggest a promising trajectory. As she continues to publish, patent, and collaborate, her work is likely to inform clinical practices and shape future therapeutic strategies. Moreover, her early career success serves as an inspiration for aspiring researchers, especially women in science, who look to combine academic excellence with social impact. Her legacy will likely be defined not only by the quality of her research but also by her dedication to innovation, mentorship, and translational science.

Notable Publications

U50 488H KOR agonist reduces cartilage degradation, chondrocyte hypertrophy and bone loss in osteoarthritis

Authors: Shradha Sinha; Anirban Sardar; Shikha Verma; Geeta Dhaniya; Ritu Trivedi

Journal: International Immunopharmacology

Year: 2025

Dr. Luciano Fusco | Immunology | Best Research Article Award

Published on by Leadership and Management

Dr. Luciano Fusco | Immunology | Best Research Article Award

CONICET y UNNE, Argentina

Author Profile

Orcid 

🎓 Early Academic Pursuits

Dr. Luciano Sebastian Fusco, born on January 2, 1986, in Corrientes, Argentina, has consistently demonstrated a deep passion for science and a commitment to understanding biochemical processes from an early stage in his career. He pursued his foundational studies at the National University of the Northeast (UNNE), where he earned his degree as a Biochemist in 2010. He continued on this academic trajectory, completing a Ph.D. in Chemical Sciences at UNNE in 2015, a decision that marked a turning point in his scientific journey. During this period, Dr. Fusco began his in-depth exploration of snake venom toxicology and immunology—fields that would come to define his career. In addition to his formal degrees, he expanded his academic horizons by completing over 20 specialized postgraduate courses, focusing on immunotoxicology, proteomics, biotechnology, and pedagogical training for higher education, laying a solid foundation for both research and teaching.

🧪 Professional Endeavors

Dr. Fusco currently serves as an Adjunct Researcher at CONICET—Argentina’s most prestigious scientific institution—and as a faculty member at UNNE’s Faculty of Exact and Natural Sciences and Surveying. Over the past 15 years, he has cemented his place as an authority in snakebite toxicology, immunology, and protein chemistry, tackling one of the world’s most neglected tropical diseases. His work combines rigorous laboratory research with practical applications in public health, particularly in developing more effective antivenoms. Dr. Fusco’s scientific career includes strong collaborative links with leading international institutions such as UNICAMP, Fiocruz, and Butantan Institute in Brazil, and the Institute of Biomedicine of Valencia (IBV–CSIC) in Spain. These collaborations have enriched his scientific output and brought global perspectives into his lab in Argentina, positioning him as a bridge between Latin American and European scientific networks.

🔬 Contributions and Research Focus

At the heart of Dr. Fusco’s research is a relentless drive to innovate antivenom production techniques and make them more efficient, affordable, and widely available in regions where snakebites are a major health issue. His projects focus on immunological strategies that incorporate nanostructured adjuvants, aiming to enhance the body’s immune response and increase the efficacy of antivenoms. His groundbreaking investigations have led to the development of experimental antivenoms using novel adjuvants such as CpG-ODN and ascorbyl palmitate, combining cutting-edge immunology with tangible health benefits. He has authored or co-authored more than 15 peer-reviewed publications, contributing significantly to the academic discourse on venom immunogenicity, PLA2 enzyme inhibition, and venom component characterization.

🏅 Accolades and Recognition

Dr. Fusco’s scientific excellence has been consistently recognized through competitive funding and research support from institutions like CONICET, FONCYT, SGCyT, and the Royal Society of Tropical Medicine and Hygiene (RSTMH) in the UK. The RSTMH Early Career Grant he received in 2022 is a testament to his international credibility and the global relevance of his research. These accolades not only reflect the scientific value of his work but also acknowledge his growing leadership in the field of neglected diseases and biomedical innovation.

🌎 Impact and Influence

The societal relevance of Dr. Fusco’s research is profound. In regions such as Latin America, where snakebites are a significant public health burden, his work contributes to saving lives and improving the quality of emergency response systems. By pushing for more immunogenic and affordable antivenoms, he is directly addressing gaps in health equity. Moreover, his dedication to human resource development is notable; he has mentored doctoral students, undergraduate researchers, and research fellows, effectively shaping the next generation of biomedical scientists in Argentina. His interdisciplinary and collaborative approach encourages knowledge sharing across borders, institutions, and cultures.

🌱 Legacy and Future Contributions

Looking forward, Dr. Luciano Fusco is poised to leave a lasting legacy in the realm of immunotherapeutics and venom research. His scientific endeavors will likely continue to evolve, incorporating tools from biotechnology, nanomedicine, and systems biology to refine and revolutionize antivenom production. Equally important is his role as an educator and mentor, ensuring that the future of biochemical research in Argentina remains vibrant and globally connected. His work not only uplifts national scientific capacity but also aligns with global health priorities such as reducing mortality from neglected tropical diseases.

📝Notable Publications

Venomic and F(ab’)₂ antivenomic studies of Bothrops alternatus venom proteins

Author(s): Luciano S. Fusco, Emidio Beraldo-Neto, Juan J. Calvete, Libia Sanz, Laura C. Lanari, Carolina Lorente, Laura C. Leiva, Daniel Pimenta, Adolfo R. de Roodt, Davinia Pla
Journal: International Journal of Biological Macromolecules
Year: 2025

Evaluation of a nanostructured CpG-ODN/ascorbyl palmitate as a safe and effective adjuvant for anticrotalic PLA2 serum

Author(s): Luciano S. Fusco, Gisela L. Lopez, Franco Maslovski, Sofía Brignone, María G. Chaves, Juan J. Calvete, Yanet G. Franco, David Hernandez, Andrea Van de Velde, Constanza Marin et al.
Journal: Transactions of The Royal Society of Tropical Medicine and Hygiene
Year: 2025

 Ascorbyl palmitate (ASC16) as a potential inhibitor of toxicity induced by Crotalus durissus terrificus venom

Author(s): Franco Maslovski, Emilio Angelina, María Alonso, Laura Leiva, Luciano Fusco
Journal: Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology
Year: 2024

Potential low-impact immunogen for the production of anti-bothropic serum: Bothrops alternatus venom treated with Na₂EDTA

Author(s): Gisela Lumila Lopez, Andrea Van de Velde, David Hernández, Soledad Bustillo, Laura Leiva, Luciano Sebastian Fusco
Journal: Toxicon
Year: 2024

 CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in mice

Author(s): Luciano S. Fusco, María M. Pascual, David Hernandez, María F. Sánchez Vallecillo, María B. Arrieta, Gabriel Moron, Santiago Palma, Belkys A. Maletto, Laura C. Leiva
Journal: Toxicon
Year: 2022

Dr. Zhigang Liu | Scientific Research | Best Researcher Award

Published on by Leadership and Management

Dr. Zhigang Liu | Scientific Research | Best Researcher Award

Zhejiang University, China

Early Academic Pursuits 📚

Zhigang Liu’s academic journey began with a strong foundation in preventive medicine at Huazhong University of Science and Technology. His undergraduate studies from 2006 to 2011 not only equipped him with an understanding of public health and disease prevention but also sparked his interest in the biochemical mechanisms underlying diseases. He then pursued a Ph.D. in Analytical Chemistry at the Chinese Academy of Sciences, one of China’s most prestigious research institutions. From 2011 to 2016, his doctoral work focused on advanced analytical techniques that laid the groundwork for his later specialization in metabolomics and systems medicine. His transition from preventive medicine to analytical chemistry marked a significant step in his interdisciplinary approach to medical research.

Professional Endeavors and Global Research Engagement 🌏

Following his Ph.D., Zhigang Liu embarked on a research career that took him beyond China, allowing him to gain international experience and collaborate with leading experts in the field. In 2016, he joined Imperial College London as a Research Associate in the Department of Surgery and Cancer, where he investigated the molecular and metabolic underpinnings of disease. His work at Imperial College evolved over time, and in 2020, he transitioned to the Department of Metabolism, Digestion, and Reproduction, continuing his exploration into bioinformatics, metabolomics, and gut microbiota interactions.

In 2024, he took on a prestigious role as a Professor in Systems Medicine at Zhejiang University, marking his return to China to contribute to cutting-edge research and education. At the same time, he retained strong international ties, securing a Visiting Professorship at Imperial College London. These dual appointments highlight his role as a bridge between Chinese and global research communities, facilitating collaborative efforts in medical science.

Contributions and Research Focus 🔍🧬

Zhigang Liu’s research revolves around the intricate relationship between gut microbiota, metabolism, and inflammatory diseases. His work integrates metabolomics, transcriptomics, and bioinformatics to uncover novel insights into diseases such as inflammatory bowel diseases (IBD) and immune-related colitis. He has spearheaded multiple projects examining the role of gut microbiota and metabolites in immune checkpoint inhibitor-induced colitis, a critical concern in cancer immunotherapy. His ability to combine computational analysis with experimental studies has positioned him at the forefront of precision medicine.

Through his leadership in projects funded by the National Natural Science Foundation of China (NSFC) and other institutions, he continues to drive impactful research that has the potential to reshape therapeutic strategies for inflammatory and metabolic disorders. His work not only advances scientific understanding but also paves the way for novel clinical applications.

Accolades and Recognition 🏆✨

Zhigang Liu’s research excellence has been recognized through prestigious appointments and competitive funding grants. His ability to secure high-impact research projects, both in China and internationally, speaks to his reputation as a leading scientist in systems medicine. His collaborations with Imperial College London and Zhejiang University further affirm his influence in the global scientific community.

Beyond funding and institutional recognition, his contributions are reflected in high-impact publications, conference presentations, and mentorship of young researchers. His interdisciplinary expertise has made him a sought-after collaborator in the fields of metabolomics and microbiota research.

Impact and Influence on the Scientific Community 🌱🔗

Zhigang Liu’s research has broad implications for medical science and public health. By deepening our understanding of gut microbiota and its role in disease, his work contributes to the development of targeted therapies that could transform the treatment of inflammatory and metabolic disorders. His investigations into immune checkpoint inhibitor-induced colitis are particularly significant in the field of cancer treatment, addressing critical side effects of immunotherapy.

Moreover, his role as a professor allows him to shape the next generation of scientists. His mentorship and teaching at Zhejiang University help cultivate future experts in bioinformatics, metabolomics, and systems medicine, ensuring that his legacy extends beyond his own research.

Legacy and Future Contributions 🔮🚀

As a scientist dedicated to uncovering the molecular mechanisms behind disease, Zhigang Liu’s impact is only set to grow. His ongoing projects promise to yield new insights into the interactions between gut microbiota, immune response, and metabolism. With continued international collaborations and interdisciplinary research, he is poised to make further breakthroughs in personalized medicine and disease prevention.

His vision extends beyond academia—his work has the potential to translate into clinical applications that improve patient outcomes worldwide. By bridging research and medical practice, Zhigang Liu continues to shape the future of systems medicine, leaving a lasting legacy in the field of gut microbiota research.

📝Notable Publications

 Inhibiting growth of Clostridioides difficile by restoring valerate, produced by the intestinal microbiota

Author: JAK McDonald, BH Mullish, A Pechlivanis, Z Liu, J Brignardello, D Kao, …
Journal: Gastroenterology
Year: 2018

 COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study

Author: JL Alexander, NA Kennedy, H Ibraheim, S Anandabaskaran, A Saifuddin, …
Journal: The Lancet Gastroenterology & Hepatology
Year: 2022

Deciphering molecular mechanism of silver by integrated omic approaches enables enhancing its antimicrobial efficacy in E. coli

Author: H Wang, A Yan, Z Liu, X Yang, Z Xu, Y Wang, R Wang, …
Journal: PLoS Biology
Year: 2019

Selective metabolic effects of gold nanorods on normal and cancer cells and their application in anticancer drug screening

Author: L Zhang, L Wang, Y Hu, Z Liu, Y Tian, X Wu, Y Zhao, H Tang, C Chen, …
Journal: Biomaterials
Year: 2013

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Author: S Lin, NA Kennedy, A Saifuddin, DM Sandoval, CJ Reynolds, RC Seoane, …
Journal: Nature Communications
Year: 2022